Streamlining cell line development for antibody titer analysis

During a cell line development project, Agenus UK used the Amperia platform in combination with BLI and SPR to analyze antibody titers.

The study found a good correlation between the platforms and revealed that Amperia can provide reliable clone ranking with a shorter setup time and smoother operation. The team found it particularly useful for routine analysis in early-stage workflows.

Highlights

• Over 80 samples were compared to BLI and SPR
• Results were consistent and reproducible
• Clone selection was supported during upstream development
• Reduced complexity in day-to-day titer analysis

Download the full whitepaper to learn more

About Abselion

Abselion started in 2018, at that time under the name HexagonFab, in a small corner of a laboratory at the University of Cambridge.

We set out with the humble goal to make protein research simpler. Scientists should be able to pursue their passion for discovery and innovation, rather than spend their valuable time with tedious, manual tasks. With RED we had access to the ideal technology to create this product. A product that is so compact that it could fit on every bench, and so affordable that it is accessible to everyone. Over the years we have designed, built and tested our first product Amperia and we’re proud to introduce it to the world.​

Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.